中华精神科杂志
中華精神科雜誌
중화정신과잡지
CHINESE JOURNA OF PSYCHIATRY
2010年
1期
31-36
,共6页
司天梅%舒良%于欣%马崔%王高华%白培深%刘协和%孙立忠%师建国%陈宪生%梅其一%栗克清
司天梅%舒良%于訢%馬崔%王高華%白培深%劉協和%孫立忠%師建國%陳憲生%梅其一%慄剋清
사천매%서량%우흔%마최%왕고화%백배심%류협화%손립충%사건국%진헌생%매기일%률극청
精神分裂症%抽样研究%抗精神病药%处方,药物
精神分裂癥%抽樣研究%抗精神病藥%處方,藥物
정신분렬증%추양연구%항정신병약%처방,약물
Schizophrenia%Sampling studies%Psychotropic drugs%Prescription,drug
目的 调查2006年我国10省市抗精神病药处方方式;分析4年间我国抗精神病药处方方式的变化趋势.方法 按照作者2002年的调查方法,选择10省市41所精神疾病专科医院或综合医院精神科的5898例精神分裂症门诊和住院患者,于2006年5月22-28日使用自制修订的调查问卷进行精神分裂症处方方式的现况调查.结果 (1)5898例患者中,门诊患者为2716例(46.0%);住院患者为3182例(54.0%);男3041例(51.6%),女2803例(47.5%),缺失54例数据.(2)99.1%的患者接受了抗精神病药治疗,使用频率在前7位的药物依次为:氯氮平(31.7%),利培酮(30.5%),舒必利(14.5%),氯丙嗪(10.8%),奋乃静(9.2%)、喹硫平(7.2%),氟哌啶醇(5.8%).换算为氯丙嗪等效剂量后,住院患者平均药物剂量显著高于门诊患者.(3)72.7%的患者使用第2代抗精神病药治疗;第1代抗精神病药的使用频率为38.3%;6.19%的患者接受了长效药物治疗.(4)75.6%的患者接受了单一非长效抗精神病药治疗;24.4%的患者联合使用2种或2种以上抗精神病药.(5)54.1%的患者联合了抗胆碱能药、苯二氮革类、β-受体阻断剂、抗抑郁药和心境稳定剂,主要用于控制不良反应或增效治疗.结论 第2代抗精神病药已经成为我国治疗精神分裂症的主流药物,反映出精神分裂症治疗理念和治疗技术的进展.
目的 調查2006年我國10省市抗精神病藥處方方式;分析4年間我國抗精神病藥處方方式的變化趨勢.方法 按照作者2002年的調查方法,選擇10省市41所精神疾病專科醫院或綜閤醫院精神科的5898例精神分裂癥門診和住院患者,于2006年5月22-28日使用自製脩訂的調查問捲進行精神分裂癥處方方式的現況調查.結果 (1)5898例患者中,門診患者為2716例(46.0%);住院患者為3182例(54.0%);男3041例(51.6%),女2803例(47.5%),缺失54例數據.(2)99.1%的患者接受瞭抗精神病藥治療,使用頻率在前7位的藥物依次為:氯氮平(31.7%),利培酮(30.5%),舒必利(14.5%),氯丙嗪(10.8%),奮迺靜(9.2%)、喹硫平(7.2%),氟哌啶醇(5.8%).換算為氯丙嗪等效劑量後,住院患者平均藥物劑量顯著高于門診患者.(3)72.7%的患者使用第2代抗精神病藥治療;第1代抗精神病藥的使用頻率為38.3%;6.19%的患者接受瞭長效藥物治療.(4)75.6%的患者接受瞭單一非長效抗精神病藥治療;24.4%的患者聯閤使用2種或2種以上抗精神病藥.(5)54.1%的患者聯閤瞭抗膽堿能藥、苯二氮革類、β-受體阻斷劑、抗抑鬱藥和心境穩定劑,主要用于控製不良反應或增效治療.結論 第2代抗精神病藥已經成為我國治療精神分裂癥的主流藥物,反映齣精神分裂癥治療理唸和治療技術的進展.
목적 조사2006년아국10성시항정신병약처방방식;분석4년간아국항정신병약처방방식적변화추세.방법 안조작자2002년적조사방법,선택10성시41소정신질병전과의원혹종합의원정신과적5898례정신분렬증문진화주원환자,우2006년5월22-28일사용자제수정적조사문권진행정신분렬증처방방식적현황조사.결과 (1)5898례환자중,문진환자위2716례(46.0%);주원환자위3182례(54.0%);남3041례(51.6%),녀2803례(47.5%),결실54례수거.(2)99.1%적환자접수료항정신병약치료,사용빈솔재전7위적약물의차위:록담평(31.7%),리배동(30.5%),서필리(14.5%),록병진(10.8%),강내정(9.2%)、규류평(7.2%),불고정순(5.8%).환산위록병진등효제량후,주원환자평균약물제량현저고우문진환자.(3)72.7%적환자사용제2대항정신병약치료;제1대항정신병약적사용빈솔위38.3%;6.19%적환자접수료장효약물치료.(4)75.6%적환자접수료단일비장효항정신병약치료;24.4%적환자연합사용2충혹2충이상항정신병약.(5)54.1%적환자연합료항담감능약、분이담혁류、β-수체조단제、항억욱약화심경은정제,주요용우공제불량반응혹증효치료.결론 제2대항정신병약이경성위아국치료정신분렬증적주류약물,반영출정신분렬증치료이념화치료기술적진전.
Objective To uncover the antipsychotic drug use patterns for treating schizophrenia in China in 2006, and the developing tendency from 2002 to 2006.Methods Based on the investigation in 2002, the same methods and same hospitals were selected, totally 41 hospitals from 10 provinces and cities.The investigation was conducted during 22th to 28th, May, 2006, using the revised self-made modified questionnaire.Results The total number of sample was 5898, including outpatients (46.0%) and inpatients (54.0% ) ( male: female = 51.6%: 47.4% ).The most common clinical characteristics were the personal and social dysfunction.Antipsychotic medication most frequently prescribed was clozapine (31.7%), subsequently were risperidone (30.5%), sulpiride (14.5%), chlorpromazine (10.8%),perphenazine (9.2%), quetiapine (7.2%) and haloperidol (5.8%) .The mean chlorpromazine equivalent dosage was higher in inpatients than outpatients.In all the patients, 75.6% were treated with mono-pharmacy, in which 72.7% with atypical antipsychotics (while 38.3% with typical drugs), and the percentage of patients with depot antipsychotics was 6.2%.24.4% of the patients were treated with 2 or more than 2 types of antipsychotics.The common concomitant medications were anticholinergic agents,benzodiazepine, β-receptor blockade, antidepressants and mood stabilizers, in order to control the adverse effects or augment the efficacy of antipsychotics.Conclusions Atypical drugs are the mainstream to treat schizophrenia in China, the tendency of antipsychotics prescription pattern matches the development of treatment outcome and treatment techniques for schizophrenia.
